Expression of influenza neuraminidase in CHO-K1 cells

International Congress Series

Volumn 1263, Issue C, 2004, Pages 568-572

  Tanimoto, Takeshi ^a   Nishimura, Yorihiro ^b   Matsuura, Yoshiharu ^b   Fuke, Isao ^a   Ishikawa, Toyokazu ^a   Yamanishi, Kouichi ^c   Tamura, Shin ichi ^a  

^a Osaka University   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cross protection; Influenza virus; Recombinant neuraminidase

Indexed keywords

EID: 70350345866     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2004.02.117     Document Type: Article

References (15)

1. Murphy, R.R, Kasel, J.A, Chanock, R.M, Association of serum anti-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. 286 (1972), 1329–1332.
2. Kilbourne, E.D, Comparative efficacy of neuraminidase-specific and conventional influenza vaccines in induction of antibody to neuraminidase in humans. J. Infect. Dis. 134 (1976), 384–394.
3. Johansson, B.E, Kilbourne, E.D, Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections. J. Infect. 162 (1990), 800–809.
4. Chen, Z, et al. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 16 (1998), 1544–1549.
5. Kilbourne, E.D, et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13 (1995), 1799–1803.
6. Johansson, B.E, Matthews, J.T, Kilbourne, E.D, Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 16 (1998), 1009–1015.
7. Johansson, B.E, Immunization with influenza A virus; hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17 (1999), 2073–2080.
8. Yoshikawa, T, et al. Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. Vaccine 21 (2002), 60–66.
9. Johansson, B.E, Price, P.M, Kilbourne, E.D, Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine 13 (1995), 841–845.
10. Deroo, T, Jou, W, Fiers, W, Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 14 (1996), 561–569.
11. Martinet, W, et al. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur. J. Biochem. 247 (1997), 332–338.
12. Niwa, H, Yamamura, K, Miyazaki, J, Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991), 193–199.
13. Gerentes, L, Kessler, N, Aymard, M, A sensitive and specific ELISA immunocapture assay for rapid quantitation of influenza A/H3N2 neuraminidase protein. J. Virol. Methods 73 (1998), 185–195.
14. Potier, M, et al. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acetyl neuraminate) substrate. Anal. Biochem. 94 (1979), 287–296.
15. Tamura, S.-I, Kurata, T, Mucosal immune responses to influenza viruses. Hayase, Y, (eds.) Recent Advances in Influenza Virus Research, 2002, Research Signpost, Trivandrum, India, 143–160.